Sanofi ‘Strongly Disagrees’ With EMA Rejection Of NAS Status For Nexviadyme

Sanofi argues that the European Medicines Agency applies a narrow interpretation of its new active substance principles which is not appropriate for biological therapies, and that the regulator fails to consider the challenges of conducting clinical research in rare diseases.

Doctors and medical researchers on conference meeting, discussing possible solutions for resolving a world health crisis.
Sanofi says the CHMP's rejection of NAS status fails to recognize and reward innovation • Source: Alamy

Sanofi Genzyme is urging the European Medicines Agency to redefine the methodology it uses to assess the new active substance (NAS) status of biological products, especially those for rare diseases, after the regulator concluded that the company’s Pompe disease drug, Nexviadyme (avalglucosidase alfa), did not qualify as a NAS.

“Avalglucosidase alfa could not be considered to be a new active substance because there was not enough difference between avalglucosidase...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography